

FEb 13 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket: BOE=1

**RECEIVED**

In re Application of: ) Conf. No.:  
Alessandra BOE et al )  
Appln. No.: 09/687,122 ) Art Unit: 1646  
Filed: October 13, 2000 ) Examiner: J. Murphy  
For: TNF RECEPTOR AND STEROID ) Washington, D.C.  
HORMONE IN A COMBINED )  
THERAPY ) February 13, 2003

FEB 19 2003

TECH CENTER 1600/2900

13

**TERMINAL DISCLAIMER**

Honorable Commissioner for Patents  
Washington, D.C. 20231

Sir:

Applied Research Systems ARS Holding N.V., a corporation of the Country of the Netherlands Antilles, having a principal place of business at Curacao, Netherlands Antilles, (hereinafter referred to as "Assignee"), is the owner of 100% of the entire right, title and interest in the above-identified application and any patent to be granted thereon. Assignee, through its undersigned attorney of record, hereby disclaims the terminal part of any patent granted on the above-identified application which would extend beyond the expiration date of the full statutory term of United States Patent No. 6,225,300, plus any extension thereof which may be subsequently granted, and hereby agrees that any patent so granted on the above-

02/14/2003 WASFAM1 00000045 09687122

02 FC:1814

110.00 OP

identified application shall be enforceable only for and during such period that said patent is commonly owned with United States Patent No. 6,225,300, this agreement to run with any patent granted on the above-identified application and to be binding upon the grantor, its successors or assigns. Assignee does not disclaim any terminal part of any patent granted on the above-identified application prior to the expiration date of the full statutory term of United States Patent No. 6,225,300 in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. §1.321(1), has all claims cancelled by reexamination certificate, or is otherwise terminated prior to expiration of its full statutory term, except for the separation of legal title stated above. This terminal disclaimer is being made without waiver of petitioner's rights under 35 U.S.C. §156, or elsewhere, which may be available to extend the term of any patent granted on the above-identified application beyond the date set by this terminal disclaimer (37 C.F.R. §1.775(a)).

It is Assignee's intent that the amount of time disclaimed and the scope of the common ownership clause be the minimum required by law and this document is to be construed to effectuate said intent. No admission is made that any claim of

the above-identified application is obvious over any claim of

Patent No. 6,225,300.


The statutory disclaimer fee of \$110.00 per 37 C.F.R.

\$1.20(d) is attached.

Respectfully submitted,

BROWDY AND NEIMARK, P.L.L.C.  
Attorneys for Applicant(s)

By



Roger L. Browdy  
Registration No. 25,618

RLB:rd  
Telephone No.: (202) 628-5197  
Facsimile No.: (202) 737-3528  
G:\bn\s\ser1\boe1A\pto\TermDisclaimer.doc